Health Canada approves Pluvicto for prostate cancer treatment

2018 12 11 00 02 7009 Atom Nuclear Lab 400

Health Canada has approved lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy (Pluvicto, Novartis) for the treatment of patients with metastatic prostate cancer.

The radiopharmaceutical drug is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other anticancer therapies, such as androgen receptor therapy or taxane-based chemotherapy.

Prostate cancer is the most diagnosed cancer among Canadian men and is the third leading cause of cancer-related death in men in Canada.

Pluvicto was approved by the U.S. Food and Drug Administration in March.

Page 1 of 436
Next Page